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ANNOUNCEMENT 
The International Melanoma Conference, Meial1oma- The Way Forward. will be held at the 
Sheraton Brisbane Hotel, Queensland, Australia 6-9 April 1994. The conference will review 
the most important areas of advancing knowledge in melanoma biology, genetics, etiology, 
clinical care, and prevention. Recommendations for high-priori ty activities over the next 5 -10 
years in respect to research, development, and implementation at both clinical and population 
levels will be formulated. For further information and/or a copy of the abstract guidelines for 
proffered papers or posters please write to International Melanoma Conference, P.O. Box 1280 
Milton, Queensland, 4064, Australia, Telephone: +6173690477. Facsimile: +617 3691512. 
Please note the deadline for receipt of abstracts in camera-ready format is 1 December 1993. 
